Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,873 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diagnosis of Melanoma Clear all
Completed Phase 2 Interventional Results available

RFT-5-dgA in Patients With Metastatic Melanoma

NCT00314093
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
RFT5pdgA
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 31, 2026, 10:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555
View directory record Official record
Conditions
Melanoma
Interventions
ABP 206, Nivolumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Long Beach, California • Fort Wayne, Indiana • Baton Rouge, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Not listed Not applicable Interventional

Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma

NCT00459849
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Intraoperative ultrasonography
Procedure
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 9, 2008 · Synced Oct 31, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

CP-675,206 In Patients With Advanced Melanoma

NCT00086489
View directory record Official record
Conditions
Malignant Melanoma
Interventions
CP-675,206
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 31, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019448
View directory record Official record
Conditions
Stage IV Melanoma, Recurrent Melanoma
Interventions
gp100 antigen, interleukin-2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
1998 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 31, 2026, 10:27 AM EDT
Completed No phase listed Observational

Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

NCT05874817
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 31, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

NCT00704938
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, autologous dendritic cell-adenovirus p53 vaccine, filgrastim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 31, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

NCT00818480
View directory record Official record
Conditions
Prostate Cancer, Melanoma, Non-Hodgkin's Lymphoma
Interventions
YM155
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 31, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

NCT01435369
View directory record Official record
Conditions
Melanoma, Malignant Melanoma
Interventions
CT-011
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
New Haven, Connecticut • Tampa, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 31, 2026, 10:27 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

NCT07160335
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Interventions
HLX17, US-sourced Keytruda®
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years to 85 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

NCT01979523
View directory record Official record
Conditions
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Trametinib, Uprosertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

NCT02308020
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
Interventions
Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Duarte, California • La Jolla, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 31, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NCT04068896
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions
NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 31, 2026, 10:27 AM EDT
Withdrawn Phase 1 Interventional

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

NCT04955262
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
Biological · Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 31, 2026, 10:27 AM EDT
Completed No phase listed Observational

A Follow-up Study of Women Evaluated and Treated for Infertility

NCT00342446
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Colorectal Cancer, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
44 Years to 88 Years · Female only
Enrollment
12,193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 31, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

NCT07288203
View directory record Official record
Conditions
Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
Interventions
Lifileucel
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dinaciclib in Treating Patients With Stage III-IV Melanoma

NCT01026324
View directory record Official record
Conditions
Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
dinaciclib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 31, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

NCT01941927
View directory record Official record
Conditions
Melanoma
Interventions
Trametinib (GSK1120212), GSK2141795
Drug
Lead sponsor
Adil Daud
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 31, 2026, 10:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

NCT01590069
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Aerosolized Aldesleukin, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Not listed Phase 2 Interventional

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

NCT00746746
View directory record Official record
Conditions
Melanoma
Interventions
HyperAcute vaccine, Pegylated Interferon-Alpha 2b
Biological · Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 13, 2011 · Synced Oct 31, 2026, 10:27 AM EDT
Active, not recruiting Phase 1 Interventional

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

NCT01586403
View directory record Official record
Conditions
Melanoma
Interventions
Dose 1, Dose 2, Dose 3, Dose 4
Biological
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 31, 2026, 10:27 AM EDT
Withdrawn Phase 2 Interventional

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

NCT04995094
View directory record Official record
Conditions
Pathologic Stage III Cutaneous Melanoma AJCC v8
Interventions
Imprime PGG, Pembrolizumab
Biological
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
La Jolla, California • Whittier, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 31, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Trial of pIL-12 Electroporation Malignant Melanoma

NCT01502293
View directory record Official record
Conditions
Melanoma
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 31, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma

NCT00323206
View directory record Official record
Conditions
Malignant Melanoma
Interventions
IL-12p DNA, Intratumoral Electroporation
Biological · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 31, 2026, 10:27 AM EDT